CL2023003605A1 - Conjugados de neodegradador-anticuerpo anti-cd33 - Google Patents
Conjugados de neodegradador-anticuerpo anti-cd33Info
- Publication number
- CL2023003605A1 CL2023003605A1 CL2023003605A CL2023003605A CL2023003605A1 CL 2023003605 A1 CL2023003605 A1 CL 2023003605A1 CL 2023003605 A CL2023003605 A CL 2023003605A CL 2023003605 A CL2023003605 A CL 2023003605A CL 2023003605 A1 CL2023003605 A1 CL 2023003605A1
- Authority
- CL
- Chile
- Prior art keywords
- neodegrader
- antibody conjugates
- compositions
- conjugates
- neodegraders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202272P | 2021-06-03 | 2021-06-03 | |
| US202163282588P | 2021-11-23 | 2021-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003605A1 true CL2023003605A1 (es) | 2024-05-03 |
Family
ID=84323935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003605A CL2023003605A1 (es) | 2021-06-03 | 2023-12-01 | Conjugados de neodegradador-anticuerpo anti-cd33 |
| CL2026000399A CL2026000399A1 (es) | 2021-06-03 | 2026-02-10 | Conjugados de neodegradador-anticuerpo anti-cd33. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2026000399A CL2026000399A1 (es) | 2021-06-03 | 2026-02-10 | Conjugados de neodegradador-anticuerpo anti-cd33. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240252671A1 (https=) |
| EP (1) | EP4346910A4 (https=) |
| JP (1) | JP2024521919A (https=) |
| KR (1) | KR20240042598A (https=) |
| AU (1) | AU2022284372A1 (https=) |
| CA (1) | CA3222185A1 (https=) |
| CL (2) | CL2023003605A1 (https=) |
| CO (1) | CO2023016712A2 (https=) |
| IL (1) | IL308812A (https=) |
| MX (1) | MX2023014282A (https=) |
| PE (1) | PE20250159A1 (https=) |
| TW (1) | TW202313022A (https=) |
| WO (1) | WO2022254377A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119212733A (zh) * | 2022-05-18 | 2024-12-27 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| EP4667463A1 (en) * | 2023-02-15 | 2025-12-24 | CSPC Megalith Biopharmaceutical Co., Ltd. | Domide molecular glue derivative and use thereof |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| WO2025085489A1 (en) * | 2023-10-17 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2358697E (pt) * | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| PT2822575T (pt) * | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| JP2018516950A (ja) * | 2015-06-12 | 2018-06-28 | イミュンジーン, インコーポレイテッドImmunGene, Inc. | がん治療のための集中インターフェロン免疫療法 |
| CN104994263B (zh) * | 2015-06-30 | 2016-12-28 | 广东欧珀移动通信有限公司 | 一种摄像装置及具有该摄像装置的终端 |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
-
2022
- 2022-06-02 AU AU2022284372A patent/AU2022284372A1/en active Pending
- 2022-06-02 PE PE2023003198A patent/PE20250159A1/es unknown
- 2022-06-02 EP EP22815474.6A patent/EP4346910A4/en active Pending
- 2022-06-02 JP JP2023574587A patent/JP2024521919A/ja active Pending
- 2022-06-02 MX MX2023014282A patent/MX2023014282A/es unknown
- 2022-06-02 WO PCT/IB2022/055168 patent/WO2022254377A1/en not_active Ceased
- 2022-06-02 KR KR1020247000100A patent/KR20240042598A/ko active Pending
- 2022-06-02 US US18/566,805 patent/US20240252671A1/en active Pending
- 2022-06-02 CA CA3222185A patent/CA3222185A1/en active Pending
- 2022-06-02 IL IL308812A patent/IL308812A/en unknown
- 2022-06-02 TW TW111120735A patent/TW202313022A/zh unknown
-
2023
- 2023-12-01 CL CL2023003605A patent/CL2023003605A1/es unknown
- 2023-12-01 CO CONC2023/0016712A patent/CO2023016712A2/es unknown
-
2026
- 2026-02-10 CL CL2026000399A patent/CL2026000399A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521919A (ja) | 2024-06-04 |
| AU2022284372A9 (en) | 2024-01-11 |
| CL2026000399A1 (es) | 2026-03-20 |
| MX2023014282A (es) | 2024-02-27 |
| TW202313022A (zh) | 2023-04-01 |
| CO2023016712A2 (es) | 2024-02-26 |
| IL308812A (en) | 2024-01-01 |
| AU2022284372A1 (en) | 2023-12-14 |
| EP4346910A4 (en) | 2026-05-06 |
| US20240252671A1 (en) | 2024-08-01 |
| PE20250159A1 (es) | 2025-01-22 |
| EP4346910A1 (en) | 2024-04-10 |
| WO2022254377A1 (en) | 2022-12-08 |
| CA3222185A1 (en) | 2022-12-08 |
| KR20240042598A (ko) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023016712A2 (es) | Conjugados de neodegradador-anticuerpo anti-cd33 | |
| MX2023014284A (es) | Conjugados de neodegradadores. | |
| CL2023001800A1 (es) | Conjugados anticuerpo-fármaco específicos para tumores con claudina 18.2 | |
| MX2022011825A (es) | Conjugados neodegradadores. | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| MX2021007620A (es) | Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1). | |
| MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
| AR113224A1 (es) | Conjugados de anticuerpo que comprenden un agonista de sting | |
| MX2023013995A (es) | Conjugados de anticuerpo y antraciclina. | |
| CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| CL2025000403A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| BR112022008756A2 (pt) | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso | |
| CL2024002658A1 (es) | Moléculas de unión contra fralfa | |
| MX2020010110A (es) | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. | |
| MX2025000550A (es) | Conjugados anticuerpo-fármaco que se unen a la proteína 1 que contiene el dominio cub (cdcp1) y usos de los mismos | |
| CO2025008154A2 (es) | Conjugados anticuerpo–fármaco anti–cea y métodos de uso | |
| EP4294441A4 (en) | ANTI-CLDN18.2 ANTIBODY CONJUGATES | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| MX2025003990A (es) | Conjugados neodegradadores | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos | |
| MX2024011128A (es) | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. | |
| CO2023009965A2 (es) | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina |